Sequana Medical NV is a commercial stage medical device company, which engages in the design, development, manufacture, and commercialization of medical device. The company is headquartered in Ghent, Oost-Vlaanderen and currently employs 48 full-time employees. The company went IPO on 2019-02-11. The firm focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.
Follow-Up Questions
Sequana Medical NV의 CEO는 누구입니까?
Ian Crosbie은 2019부터 회사에 합류한 Sequana Medical NV의 Chief Executive Officer입니다.
SQNMF 주식의 가격 성능은 어떻습니까?
SQNMF의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
Sequana Medical NV의 주요 사업 주제나 업종은 무엇입니까?
Sequana Medical NV은 Health Care 업종에 속하며, 해당 부문은 Health Care입니다
Sequana Medical NV의 시가총액은 얼마입니까?
Sequana Medical NV의 현재 시가총액은 $NaN입니다
Sequana Medical NV는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 6명의 분석가가 Sequana Medical NV에 대한 분석 평가를 실시했으며, 이는 4명의 강력한 매수, 4명의 매수, 2명의 보유, 0명의 매도, 그리고 4명의 강력한 매도를 포함합니다
